Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
about
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsContrasting Adult and Infant Immune Responses to HIV Infection and VaccinationThe evolution within usStructural insights on the role of antibodies in HIV-1 vaccine and therapyA Blueprint for HIV Vaccine DiscoveryAntibody responses to envelope glycoproteins in HIV-1 infectionThe Antibody Response against HIV-1Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapyVaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding SiteHIV-1 receptor binding site-directed antibodies using a VH1-2 gene segment orthologue are activated by Env trimer immunizationStructural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsA Conformational Switch in Human Immunodeficiency Virus gp41 Revealed by the Structures of Overlapping Epitopes Recognized by Neutralizing AntibodiesInteractions between Lipids and Human Anti-HIV Antibody 4E10 Can Be Reduced without Ablating Neutralizing ActivityStructural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based ImmunogensStructural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesStructural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class AntibodiesDelineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralizationStructure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological TheoryNeutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from IndiaStabilizing exposure of conserved epitopes by structure guided insertion of disulfide bond in HIV-1 envelope glycoproteinHuman antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesPrevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccineA directed molecular evolution approach to improved immunogenicity of the HIV-1 envelope glycoproteinPriming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesComparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studiesRational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine developmentAppreciating HIV type 1 diversity: subtype differences in Env.Current views on the potential for development of a HIV vaccine.A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitopePolyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infectionThe cat and mouse of HIV-1 antibody escape.Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.
P2860
Q24635002-4AFA2E2A-74E1-4BBE-9113-F92824083A3DQ26776518-72B96E0A-863B-40C4-8181-EB906D5BF25DQ26801603-52A42CA9-4606-4782-9B00-D9B07E1DF477Q26829461-F9880BF1-2510-4D14-BA7C-01FA263F4D1AQ26829865-836E72D0-D40E-44E1-88C6-5C8497A7D3DAQ26991572-46BDCB03-3757-43BF-8722-A1D497C59602Q27000889-79EDE228-D90C-4382-BE23-300BF76C9FB8Q27313556-99A224AA-87E4-4369-B212-3EEA11F48F98Q27319450-ECEBEC20-DF58-41B2-8934-827066F78AFDQ27324184-FD34E2AF-D628-42D9-8107-246A716292E4Q27643993-4D1140AE-6F14-4E1F-8F21-EA77AEAD0554Q27655865-D307D9BE-4032-4C50-8236-49B0344A8F0DQ27658138-E3CCB93C-BF37-4123-B1A4-8DAEF3814796Q27658173-212E8E85-8BC2-42B5-9624-7262008253F4Q27658449-03DFDDD9-451B-4B4C-A821-37F84BF5139EQ27662155-DE1A6B56-2F1D-4840-9E42-3F04603DA51BQ27662167-75D033B9-78C3-48EF-8B23-8D861247A5D2Q27663293-44A97D6B-581A-4FA3-B5F7-B36FFEFD502FQ27674878-C0D948C4-7575-4762-9985-9F2DF00BB215Q27678312-15B114CA-D20E-4B05-8198-04A6690EBE8CQ27679353-9595D4DD-BB2E-4CA4-9519-7FFFDDF00725Q27684578-ED63FACD-C0F0-46CB-AE4C-FF66904F5CA6Q28071559-82CDF03B-38AC-4909-83A5-10FF5E7C5C1DQ28483205-1628330B-21C1-47B6-94F1-C2DDDD9011C4Q28534454-7FFBCA05-3339-4CA6-9584-6A02B8DEE1D4Q28602877-EE32D847-BA9F-498C-8D6E-B8233FF178B7Q28742137-C81E4959-0CE6-400B-BB59-6045AE4EBC28Q28743092-99B7A961-2C94-44D2-98F3-9189F5E8B112Q28749120-BDC2FAE5-55B6-443B-B9F2-20BE52A56D6BQ28749755-3A111BF5-E120-49BE-8400-BF4C4E86CEECQ29619511-7C990CED-7F31-42FF-A1D3-90B01D999A89Q30234577-19117CD9-E3A1-444D-87AD-14CFF07D260BQ30355260-53B581C0-C118-41E3-945C-CAC461A307D9Q30375834-A6FB4513-6B4C-4F3A-A33B-086A0CF81048Q30397595-722BDC2C-92CA-4F85-BA32-9E0E98627A94Q31132248-E94A610D-DAA3-4FFD-BF50-7AAE23895C0DQ33417195-60164C55-EC0A-44E1-BA30-77AA35A2738FQ33479167-BD60944F-3924-4CB1-8113-7C69C8FB4480Q33504607-225016D4-3120-479A-A986-F439A82024E9Q33518005-027A9E03-AEBE-4318-81D8-80311E81E4D4
P2860
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Profiling the specificity of n ...... virus type 1 subtypes B and C.
@en
type
label
Profiling the specificity of n ...... virus type 1 subtypes B and C.
@en
prefLabel
Profiling the specificity of n ...... virus type 1 subtypes B and C.
@en
P2093
P2860
P50
P356
P1433
P1476
Profiling the specificity of n ...... virus type 1 subtypes B and C.
@en
P2093
Blake Wood
Cory Nathe
Diane Wycuff
Douglas Richman
Elizabeth A Lybarger
Emma T Crooks
Georgia D Tomaras
James E Robinson
James M Binley
Julie M Decker
P2860
P304
11651-11668
P356
10.1128/JVI.01762-08
P407
P577
2008-09-24T00:00:00Z